Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Apalutamide
Enzalutamide
Non-metastatic castration resistant prostate cancer
nmCRPC
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
received:
22
02
2024
accepted:
04
05
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Phase III clinical trials demonstrated the efficacy of enzalutamide and apalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and PSA doubling time ≤10 months. Although these drugs have been shown to vary in their adverse event (AE) profiles, the differences in their efficacy profiles remain to be evaluated. Therefore, this retrospective study was conducted to evaluate the efficacy of these drugs in patients with nmCRPC. This study evaluated 191 patients with nmCRPC treated with enzalutamide (n = 137) or apalutamide (n = 54) in the first-line setting at Jikei University Hospital or its affiliated hospitals between May 2014 and November 2022. Endpoints were defined as oncological outcomes (i.e., PSA response, PFS, PSA-PFS, MFS, CSS, and OS) and AEs. No significant differences were noted in patient backgrounds between the two groups. Patients exhibiting a maximum PSA response of >50% and >90% accounted for 74.5% and 48.9% of patients in the enzalutamide group, and 75.9% and 42.6% of patients in the apalutamide group, respectively, with no significant difference between the groups. The median PSA-PFS was 10 months in the enzalutamide group but not in the apalutamide group, with no significant difference between the groups (P = 0.48). No significant differences were observed in MFS, CSS, or OS between the groups. Patients reporting AEs of all grades and grade 3 or higher accounted for 56.2% and 4.3% of those in the enzalutamide group and 57.4% and 7.4% of those in the apalutamide group, respectively. The most common AE was fatigue (26.3%) in the enzalutamide group and skin rash (27.8%) in the apalutamide group. In this retrospective study of their efficacy and safety, enzalutamide and apalutamide were shown to exhibit comparable oncological outcomes but quite different AE profiles, suggesting that their differential use may be warranted based on these findings.
Identifiants
pubmed: 38769191
doi: 10.1007/s10147-024-02548-6
pii: 10.1007/s10147-024-02548-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
doi: 10.3322/caac.21590
pubmed: 31912902
Kluth LA, Shariat SF, Kratzik C et al (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32(3):669–676. https://doi.org/10.1007/s00345-013-1157-5
doi: 10.1007/s00345-013-1157-5
pubmed: 23999854
Sternberg CN, Fizazi K, Saad F et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197–2206. https://doi.org/10.1056/NEJMoa2003892
doi: 10.1056/NEJMoa2003892
pubmed: 32469184
Smith MR, Saad F, Chowdhury S et al (2021) Apalutamide and overall survival in prostate cancer. Eur Urol 79(1):150–158. https://doi.org/10.1016/j.eururo.2020.08.011
doi: 10.1016/j.eururo.2020.08.011
pubmed: 32907777
Fizazi K, Shore N, Tammela TL et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383(11):1040–1049. https://doi.org/10.1056/NEJMoa2001342
doi: 10.1056/NEJMoa2001342
pubmed: 32905676
Mori K, Kimura T, Fukuokaya W et al (2020) Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. Int J Clin Oncol 25(3):479–485. https://doi.org/10.1007/s10147-019-01541-8
doi: 10.1007/s10147-019-01541-8
pubmed: 31512007
Mori K, Kimura T, Ito K et al (2018) Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. Prostate 78(10):766–772. https://doi.org/10.1002/pros.23534
doi: 10.1002/pros.23534
pubmed: 29635810
Mori K, Mostafaei H, Pradere B et al (2020) Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol 25(11):1892–1900. https://doi.org/10.1007/s10147-020-01777-9
doi: 10.1007/s10147-020-01777-9
pubmed: 32924096
pmcid: 7572325
Mori K, Quhal F, Katayama S et al (2022) Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urol Nephrol 74(3):292–301. https://doi.org/10.23736/s2724-6051.21.04431-1
doi: 10.23736/s2724-6051.21.04431-1
pubmed: 34308608
Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159. https://doi.org/10.1200/jco.2007.12.4487
doi: 10.1200/jco.2007.12.4487
pubmed: 18309951
Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/NEJMoa1503747
doi: 10.1056/NEJMoa1503747
pubmed: 26244877
pmcid: 4562797
Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002
doi: 10.1016/j.eururo.2016.08.002
pubmed: 27591931
Mori K, Mostafaei H, Sari Motlagh R et al (2022) Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int 129(4):423–433. https://doi.org/10.1111/bju.15507
doi: 10.1111/bju.15507
pubmed: 34171173
Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465–2474. https://doi.org/10.1056/NEJMoa1800536
doi: 10.1056/NEJMoa1800536
pubmed: 29949494
pmcid: 8288034
Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418. https://doi.org/10.1056/NEJMoa1715546
doi: 10.1056/NEJMoa1715546
pubmed: 29420164
Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262. https://doi.org/10.1016/j.eururo.2020.09.042
doi: 10.1016/j.eururo.2020.09.042
pubmed: 33172724
Cornford P, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263–282. https://doi.org/10.1016/j.eururo.2020.09.046
doi: 10.1016/j.eururo.2020.09.046
pubmed: 33039206
Ji C, Guha M, Zhu X et al (2020) Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol 33(1):211–222. https://doi.org/10.1021/acs.chemrestox.9b00247
doi: 10.1021/acs.chemrestox.9b00247
pubmed: 31538772
Guha M, Ji C, Zhu X et al (2019) 1892P—Enzalutamide (ENZA) and apalutamide (APA) in vitro chemical reactivity studies and activity in a mouse drug allergy model (MDAM). Ann Oncol 30:v767–v768. https://doi.org/10.1093/annonc/mdz268.019
doi: 10.1093/annonc/mdz268.019
Moilanen AM, Riikonen R, Oksala R et al (2015) Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5:12007. https://doi.org/10.1038/srep12007
doi: 10.1038/srep12007
pubmed: 26137992
pmcid: 4490394
Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx J Am Soc Exp NeuroTher 2(4):541–553. https://doi.org/10.1602/neurorx.2.4.541
doi: 10.1602/neurorx.2.4.541
Yu J, Zhou P, Hu M et al (2019) Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. Eur J Med Chem 182:111608. https://doi.org/10.1016/j.ejmech.2019.111608
doi: 10.1016/j.ejmech.2019.111608
pubmed: 31437779
Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25(24):7448–7454. https://doi.org/10.1158/1078-0432.ccr-19-1050
doi: 10.1158/1078-0432.ccr-19-1050
pubmed: 31511295